Since patients who regularly take NSAIDS may use sucralfate because of its cytoprotective properties, we examined the influence of this compound on the pharmacokinetics of diclofenac.
Potassium ...diclofenac (105 mg) was administered orally to eighteen healthy male volunteers with or without a 5-day pre-treatment with sucralfate (2000 mg twice daily). Blood samples were collected at intervals post-dose and serum concentrations of diclofenac were determined by reverse-phase h.p.l.c.
Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) 2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562) and the Cmax 1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981) with no significant delay in absorption tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0).
The short-term treatment of healthy male volunteers with sucralfate decreases potassium diclofenac bioavailability. These findings suggest that either an appropriate increase in the diclofenac intake or the use of another gastric mucosa protector must be adopted.
An oral triple therapy using sucralfate instead of a bismuth to eradicate Helicobacter pylori has yielded worse results than those obtained with conventional oral triple therapies. To date, the ...effect of sucralfate on the pharmacokinetics of nitroimidazolic compounds used in triple therapy such as with metronidazole is unknown. The aim of this study was to investigate the effect of a 5-day administration period of sucralfate (2 g b.i.d.) on metronidazole pharmacokinetics.
Fourteen healthy male volunteers were selected. The study had an open randomized 2-period crossover design with a 14-day washout period between the phases. The plasma concentration of metronidazole and its hydroxy-metabolite were measured by reverse-phase HPLC with ultraviolet detection.
No statistically significant difference was observed in any of the pharmacokinetic parameters studied in the absence and presence of sucralfate.
Our results clearly indicate that short-term treatment with sucralfate in healthy volunteers does not alter the extent or the rate of metronidazole absorption, and does not affect metronidazole clearance.
Aims Since patients who regularly take NSAIDS may use sucralfate because of its cytoprotective properties, we examined the influence of this compound on the pharmacokmetics of diclofenac.
Methods ...Potassium diclofenac (105 mg) was administered orally to eighteen healthy male volunteers with or without a 5‐day pre‐treatment with sucralfate (2000 mg twice daily). Blood samples were collected at intervals post‐dose and serum concentrations of diclofenac were determined by reverse‐phase h.p.1.c. Results Pre‐treatment with sucralfate significantly decreased both the AUC(0,8 h) 2265 ng h Ml−1 (geometric mean) (range 1815–2827)vs 1821 ng h ml−’(1295–2562) and the Cmax 1135 ng ml−1 (geometric mean) (range 898–1436) vs 701 ng ml−1 (501–981) with no significant delay in absorption tmax 1.0 h (median) (range 0.5–2.0) vs 1.0 h (0.5‐4.0)l.
Conclusions The short‐tern treatment of healthy male volunteers with sucralfate decreases potassium diclofenac bioavailability. These findings suggest that either an appropriate increase in the diclofenac intake or the use of another gastric mucosa protector must be adopted.
PDF